XYOSTED Card

Co-Pay Card Program

AS LITTLE AS $25 CO-PAY

FOR MOST COMMERCIALLY INSURED PATIENTS*

 

* Eligibility restrictions: Offer not valid for prescriptions reimbursed under any federal or state healthcare program, including Medicare, Medicaid, or any state medical assistance programs. Offer void where prohibited by law, taxed, or restricted. Offer only valid in the USA. Maximum benefit up to $125 for each prescription filled. Halozyme reserves the right to rescind, revoke, or amend this offer at any time without notice. By using this co-pay card, you demonstrate that you understand and agree to comply with the terms and conditions of this offer as put forth on this co-pay assistance card.

  • Co-pay assistance for eligible patients
  • XYOSTED® 4YOU Cash Program
  • Specialty Pharmacies
  • Free auto-injector disposal program

For more information on XYOSTED or how your patients can get access,
please visit
www.XYOSTED.com or call 1-844-XYOSTED   

Activate Co-Pay Card

Experience the benefits of choosing a Xyosted Specialty Pharmacy Partner

Xyosted Specialty Pharmacy Partners provide personalized care and support at every step.

Explore the advantages for your patients:
Specialty Pharmacy Partner
Retail Pharmacy 
Benefits investigation and prior authorization support 
More likely to apply XYOSTED co-pay card
Offers cash-pay program*
Refill reminders and re-authorization
Dedicated point of contact for office staff and patients
In-person pickup

* Available nationally through Sterling Specialty Pharmacy, and locally through ahma Rx Elmsford, NY; ahma Rx New York, NY; ahma Rx Garfield, NJ; Choice Specialty Pharmacy Sugarland, TX; Choice Specialty Pharmacy Shenandoah, TX; Goldsmith Medicenter Pharmacy St. Louis, MO; and Pharmacy at Blue Back, West Hartford, CT. 

CONSIDER A Xyosted SPECIALTY PHARMACY PARTNER

National Specialty Pharmacy 

Sterling Specialty Pharmacy
1312 Northland Dr, Ste 500
Mendota Heights, MN 55120
PH (888) 618-4126
NPI 1225548480
FX (866) 588-0371 

Regional Specialty Pharmacies 

ALABAMA

Village Discount Drug

1726 Cherokee Ave, SW, 
Suite A
Cullman, Alabama 35055
PH (256) 775-7455
NPI 1154712685
FX (256) 381-8065

CALIFORNIA

986 Pharmacy

2001 Santa Monica Blvd, Suite 100W
Santa Monica, CA 90404
PH (310) 496-7555
NPI 1912542275
FX (310) 496-1818 
ABC Pharmacy
23141 Moulton Parkway #107
Laguna Hills, CA 92653
PH (949) 916-9990
NPI 1568814630
FX (949) 377-0368
Delta Drugs
437 Fernando Ct
Glendale, CA 91204
PH (818) 309-2884
NPI 1184114654 F
FX (818) 309-2651 
Link Pharmacy
22942 Ridge Route Dr, Suite 104
Lake Forest, CA 92630
PH (949) 215-5899
NPI 1710550983
FX (949) 215-3855

CONNECTICUT

Pharmacy at Blue Back
55 Isham Rd W
Hartford, CT 06107
PH (860) 656-6229
NPI 1952061939
FX (860) 968-0013 

GEORGIA

Anchor Pharmacy
2139 Lawrenceville Highway
Decatur, GA 30033
PH (404) 600-8172
NPI 1255853784
FX (678) 732-9614  

MISSOURI

Goldsmith Medicenter Pharmacy
13354 Manchester Rd, Ste 101
Des Peres, MO 63131
PH (314) 432-5020
NPI 1245334200
FX (314) 432-5026  

NEW JERSEY

ahma Rx
85 Outwater Lane, #7
Garfield, NJ 07021
PH (862) 225-9422
NPI 1053737700
FX (862) 225-9423   

NEW YORK

ahma Rx
2381 Frederick Douglass Blvd
New York, NY 10027
PH (212) 749-6626
NPI 1649966268
FX (212) 749-6629    
ahma Rx
35 Valley Avenue
Elmsford, NY 10523
PH (914) 840-5027
NPI 1578119749
FX (914) 840-5022     
Chemist Shoppe
30-15 38th Avenue
Long Island City, NY 11101
PH (718) 472-0900, ext 2
NPI 1790073906
FX (718) 472-0909      
Silver Rod
6408 18th Avenue
Brooklyn, NY 11204
PH (718) 236-5705
NPI 1508842931
FX (718) 922-0348    

RHODE ISLAND

Atwood Pharmacy
1302 Atwood Avenue
Johnstown, RI 01929
PH (401) 864-0460
NPI 1851001085
FX (401) 300-4002   

TEXAS

Alamo Pharmacy
8832 Huebner Rd
San Antonio, TX 78240
PH (210) 314-6782
NPI 1285971622
FX (210) 314-6820    
Allied Pharmacy
1201 Creekway Dr., Suite C
Sugar Land, Tx 77478
PH (832) 365-3420
NPI 1710611686
FX (855) 595-2955    
Choice Specialty Pharmacy
1403 Hwy 6
Sugarland, TX 77478
PH (832) 944-6112
NPI 1053618199
FX (832) 944-6116     
Choice Specialty Pharmacy
8850 Six Pines Dr #150
Shenandoah, TX 77380
PH (346) 309-4800
NPI 1841613981
FX (832) 616-3489    

BEST PRACTICES FOR SUBMITTING XYOSTED PRESCRIPTIONS 

What to provide when submitting prescriptions*: 

  • Two pretreatment morning testosterone lab values below normal range 
  • Most recent testosterone lab values for established testosterone-treated patients 
  • Patient chart notes with key information (ie, previously tried and failed medications) 
  • Chart notes documenting if low pretreatment labs are not available for established testosterone-treated patients 

Requirements of individual insurance providers may vary. You may be asked to provide additional information. 

* Prior to initiating XYOSTED, confirm the diagnosis of hypogonadism by ensuring that serum testosterone concentrations have been measured in the morning on at least two separate days and that these serum testosterone concentrations are below the normal range.

FAQs & Resources

Still have unanswered questions about TRT and XYOSTED? Explore our FAQs section.

Learn More


XYOSTED® (testosterone enanthate) injection, for subcutaneous use CIII

XYOSTED INDICATIONS AND USAGE

XYOSTED (testosterone enanthate) injection is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

  • Primary hypogonadism (congenital or acquired)
  • Hypogonadotropic hypogonadism (congenital or acquired)

LIMITATIONS OF USE

  • Safety and efficacy of XYOSTED in men with “age-related hypogonadism” has not been established
  • Safety and efficacy of XYOSTED in males less than 18 years old have not been established

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

XYOSTED is contraindicated in:

  • Men with carcinoma of the breast or known or suspected carcinoma of the prostate.
  • Women who are pregnant. Testosterone can cause virilization of the female fetus when administered to a pregnant woman.
  • Men with known hypersensitivity to XYOSTED or any of its ingredients (testosterone enanthate and sesame oil).

WARNINGS AND PRECAUTIONS

Polycythemia—Increases in hematocrit, reflective of increases in red blood cell mass, may require discontinuation of XYOSTED. Check that hematocrit is not elevated prior to initiating XYOSTED. Evaluate hematocrit approximately every 3 months while the patient is on XYOSTED. If hematocrit becomes elevated, stop XYOSTED until the hematocrit decreases to an acceptable level. If XYOSTED is restarted and again causes hematocrit to become elevated, stop XYOSTED permanently. An increase in red blood cell mass may increase the risk of thromboembolic events.

Venous Thromboembolism (VTE)—There have been post-marketing reports of venous thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), in patients using testosterone products, such as XYOSTED.

In the Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study, a randomized, double-blind, placebo-controlled, cardiovascular (CV) outcomes study, compared to placebo, topical testosterone gel was associated with a higher risk of VTE (1.7% vs 1.2%) which included DVT (0.6% vs 0.5%) and PE (0.9% vs 0.5%).

Evaluate patients who report symptoms of pain, edema, warmth and erythema in the lower extremity for DVT and those who present with acute shortness of breath for PE. If a venous thromboembolic event is suspected, discontinue treatment with XYOSTED and initiate appropriate workup and management.

Worsening of Benign Prostatic Hyperplasia (BPH) and Potential Risk of Prostate Cancer—Patients with BPH treated with androgens are at an increased risk of worsening of signs and symptoms of BPH. Monitor patients with BPH for worsening signs and symptoms. Patients treated with androgens may be at an increased risk for prostate cancer. Evaluate patients for prostate cancer prior to initiating and during treatment with androgens.

Blood Pressure Increase—XYOSTED can increase blood pressure.  Ambulatory blood pressure monitoring (ABPM) demonstrated XYOSTED increased systolic/diastolic BP by an average of 3.9/1.5 mmHg from baseline after 12 weeks of treatment in clinical trials.  In patients with hypertension on antihypertensive therapy, XYOSTED increased the mean systolic/diastolic BP by 3.9/1.3  mm Hg from baseline.  

The  CV risk associated with topical testosterone gel was evaluated in TRAVERSE, a randomized, double-blind, placebo-controlled, CV outcomes study in men with a history of CV disease or multiple CV risk factors.  In TRAVERSE, topical testosterone gel increased mean systolic blood pressure by 1.8 mmHg from baseline.  However, the incidences of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction [MI] and non-fatal stroke, were similar between treatment groups (7% for topical testosterone gel vs 7.3% for placebo).

Monitor blood pressure periodically in men using XYOSTED, especially men with hypertension.  XYOSTED is not recommended for use in patients with uncontrolled hypertension.

Abuse of Testosterone and Monitoring of Serum Testosterone Concentrations—Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. Anabolic androgenic steroid abuse can lead to serious cardiovascular and psychiatric adverse reactions.

If testosterone abuse is suspected, check serum testosterone concentrations to ensure they are within therapeutic range. However, testosterone levels may be in the normal or subnormal range in men abusing synthetic testosterone derivatives. Counsel patients concerning the serious adverse reactions associated with abuse of testosterone and anabolic androgenic steroids. Conversely, consider the possibility of testosterone and anabolic androgenic steroid abuse in suspected patients who present with serious cardiovascular or psychiatric adverse events.

Not for Use in Women—Due to lack of controlled studies in women and potential virilizing effects, XYOSTED is not indicated for use in women.

Potential for Adverse Effects on Spermatogenesis—With large doses of exogenous androgens, including XYOSTED, spermatogenesis may be suppressed through feedback inhibition of pituitary follicle-stimulating hormone (FSH) which could possibly lead to adverse effects on semen parameters including sperm count. Patients should be informed of this possible risk when deciding whether to use or to continue to use XYOSTED.

Hepatic Adverse Effects—Prolonged use of high doses of orally active 17-alpha-alkyl androgens (e.g., methyltestosterone) has been associated with serious hepatic adverse effects (peliosis hepatis, hepatic neoplasms, cholestatic hepatitis, and jaundice). Peliosis hepatis can be a life-threatening or fatal complication. Long-term therapy with intramuscular testosterone enanthate, which elevates blood levels for prolonged periods, has produced multiple hepatic adenomas. XYOSTED is not known to produce these adverse effects. Nonetheless, patients should be instructed to report any signs or symptoms of hepatic dysfunction (e.g., jaundice). If these occur, promptly discontinue XYOSTED while the cause is evaluated.

Edema—Androgens, including XYOSTED, may promote retention of sodium and water. Edema with or without congestive heart failure may be a serious complication in patients with preexisting cardiac, renal, or hepatic disease. In addition to discontinuation of the drug, diuretic therapy may be required.

Gynecomastia—Gynecomastia may develop and may persist in patients being treated for hypogonadism.

Sleep Apnea—Treatment with testosterone products, including XYOSTED, may potentiate sleep apnea in some patients, especially those with risk factors such as obesity or chronic lung disease.

Lipid Changes—Changes in the serum lipid profile may require dose adjustment of lipid lowering drugs or discontinuation of testosterone therapy. Monitor the lipid profile periodically, particularly after starting testosterone therapy.

Hypercalcemia—Androgens, including XYOSTED, should be used with caution in cancer patients at risk of hypercalcemia (and associated hypercalciuria). Monitor serum calcium concentrations regularly during treatment with XYOSTED in these patients.

Decreased Thyroxine-binding Globulin—Androgens, including XYOSTED, may decrease concentrations of thyroxine-binding globulin, resulting in decreased total T4 serum concentrations and increased resin uptake of T3 and T4. Free thyroid hormone concentrations remain unchanged, however, and there is no clinical evidence of thyroid dysfunction.

Risk of Depression and Suicide—Depression and suicidal ideation and behavior, including completed suicide, have occurred during clinical trials in patients treated with XYOSTED. Advise patients and caregivers to seek medical attention for manifestations of suicidal ideation or behavior, new onset or worsening depression, anxiety, or other mood changes.

ADVERSE REACTIONS

The safety of XYOSTED was evaluated in 2 clinical studies in a total of 283 men who received weekly subcutaneous doses for up to 1 year. All patients were started on 75 mg weekly, then the dose was titrated to 50 mg or 100 mg weekly, as needed, to achieve pre-dose total testosterone concentrations of ≥350 ng/dL and <650 ng/dL.

The most commonly reported adverse reactions (>5%) were: hematocrit increased, hypertension, PSA increased, injection site bruising, and headache.

DRUG INTERACTIONS

Insulin—Changes in insulin sensitivity or glycemic control may occur in patients treated with androgens. In diabetic patients, the metabolic effects of androgens may decrease blood glucose and, therefore, may necessitate a decrease in the dose of anti-diabetic medication.

Oral Anticoagulants—Changes in anticoagulant activity may be seen with androgens, therefore, more frequent monitoring of international normalized ratio (INR) and prothrombin time are recommended in patients taking warfarin, especially at the initiation and termination of androgen therapy.

Corticosteroids—The concurrent use of testosterone with corticosteroids may result in increased fluid retention and requires careful monitoring, particularly in patients with cardiac, renal or hepatic disease.

Medications that May Also Increase Blood Pressure—Some prescription medications and nonprescription analgesic and cold medications contain drugs known to increase blood pressure. Concomitant administration of these medications with XYOSTED may lead to additional increases in blood pressure.

USE IN SPECIFIC POPULATIONS

Pregnancy—XYOSTED is contraindicated in pregnant women. Testosterone is teratogenic and may cause fetal harm when administered to a pregnant woman based on data from animal studies and its mechanism of action. Exposure of a female fetus to androgens may result in varying degrees of virilization. In animal developmental studies, exposure to testosterone in utero resulted in hormonal and behavioral changes in offspring and structural impairments of reproductive tissues in female and male offspring. These studies did not meet current standards for nonclinical development toxicity studies.

Lactation—XYOSTED is not indicated for use in females.

Females and Males of Reproductive Potential - During treatment with large doses of exogenous androgens, including XYOSTED, spermatogenesis may be suppressed through feedback inhibition of the hypothalamic-pituitary-testicular axis. Reduced fertility is observed in some men taking testosterone replacement therapy. The impact on fertility may be irreversible.

Pediatric Use—Safety and effectiveness of XYOSTED in pediatric patients less than 18 years old have not been established. Improper use may result in acceleration of bone age and premature closure of epiphyses.

Geriatric Use—There have not been sufficient numbers of geriatric patients in controlled clinical studies with XYOSTED to determine whether efficacy or safety in those over 65 years of age differs from younger subjects. Of the 283 patients enrolled in the 6-month and 1-year efficacy and safety clinical study utilizing XYOSTED, 49 (17%) were over 65 years of age. Additionally, there are insufficient long-term safety data in geriatric patients to assess the potentially increased risk of cardiovascular disease and prostate cancer. Geriatric patients treated with androgens may also be at risk for worsening of signs and symptoms of BPH.

DRUG ABUSE AND DEPENDENCE

XYOSTED contains testosterone enanthate, a Schedule III controlled substance in the Controlled Substances Act.

Abuse and misuse of testosterone are seen in male and female adults and adolescents. Testosterone, often in combination with other anabolic androgenic steroids, may be abused by athletes and bodybuilders.

Serious adverse reactions have been reported in individuals who abuse anabolic androgenic steroids, and include cardiac arrest, myocardial infarction, hypertrophic cardiomyopathy, congestive heart failure, cerebrovascular accident, hepatotoxicity, and serious psychiatric manifestations, including major depression, mania, paranoia, psychosis, delusions, hallucinations, hostility, and aggression.

The following adverse reactions have been reported in men: transient ischemic attacks, convulsions, hypomania, irritability, dyslipidemia, testicular atrophy, subfertility, and infertility.

The following adverse reactions have been reported in women: hirsutism, virilization, deepening of voice, clitoral enlargement, breast atrophy, male pattern baldness, and menstrual irregularities.

The following adverse reactions have been reported in male and female adolescents: premature closure of bony epiphyses with termination of growth, and precocious puberty.

Withdrawal symptoms can be experienced upon abrupt discontinuation in patients with addiction. Withdrawal symptoms include depressed mood, major depression, fatigue, craving, restlessness, irritability, anorexia, insomnia, decreased libido, and hypogonadotropic hypogonadism. Drug dependence in individuals using approved doses for approved indications have not been documented. 

For more information, call
1-844-XYOSTED (1-844-996-7833).

Please see full Prescribing Information and Medication Guide.
April 2025 Update.